Media Coverage

More Americans are testing positive for fentanyl use in randomized workplace drug tests, highlighting a persistent challenge for employers. The positive rate for urine tests indicating the presence of the synthetic opioid fentanyl was 1.13% in 2024. That is up from 0.91% in 2023 and double the rate in 2020, according to a recent analysis of more than eight million drug tests by Quest Diagnostics, one of the U.S.’s largest drug-testing labs.

Jeff Lusby is the general manager of healthcare IT solutions at Quest Diagnostics. With more than 29 years in healthcare IT, Lusby has extensive experience with technology implementations, from the sales journey to installation, support and account management. In his current role, he leads Quest’s Quanum Enterprise Content Solutions software business.

Corewell Health has signed on to a joint venture with Quest Diagnostics covering inpatient and outpatient lab management and the construction of a new 100,000-square-foot advanced lab facility.

Independent laboratory company Quest Diagnostics and Corewell Health entered a definitive agreement to build a jointly owned lab in Michigan. The Diagnostic Lab of Michigan would be based at the Corewell Health Southfield Center in Southfield, Michigan. It would focus on automated microbiology and high-throughput molecular testing.

Quest Diagnostics said on Monday the US Food and Drug Administration has granted breakthrough device designation for the firm's Haystack minimal residual disease (MRD) test. The tumor-informed, whole-exome sequencing assay detects circulating tumor DNA in blood to identify MRD-positive patients with stage II colorectal cancer who have received curative-intent surgical treatment and may benefit from adjuvant therapy. Quest acquired the test when it bought Haystack Oncology in 2023.

Quest Diagnostics, a provider of diagnostic information services, has been scaling its efforts in the digital pathology space through an ongoing collaboration with PathAI. “Beyond assisting the pathologist in looking at and identifying problem areas on the slide, there are a lot of AI tools that can help the pathologist become more efficient and work more quickly,” said Chad Richards, president of pathology and medical services at Quest Diagnostics.

Quest Diagnostics has completed its acquisition of some clinical testing assets from Spectra Laboratories, a subsidiary of dialysis company Fresenius Medical Care.

During Quest Diagnostics' most recent investor day presentation, President and CEO Jim Davis highlighted the sale of data and data analytics as among the fastest growing businesses within the company. As at Tricore, part of this effort is focused not only on identifying but closing patient care gaps, said David Freeman, VP and general manager of healthcare analytics solutions at the company. Using data generated by a lab, "A health plan can create a standing order for a lab test for a particular patient based on closing a gap in care," he said. If the patient then shows up at a Quest location for another service, "and that standing order exists, we can add that test and close that gap," he said.

A new Quest Diagnostics Lab has opened inside a CVS Pharmacy store in Johnston. Company officials gathered at the Putnam Pike store on Friday morning to celebrate its opening, which took place earlier this month. “This lab opened on July 11, and it is the first Quest Diagnostic Lab in Rhode Island and only the second in the nation,” said CVS Pharmacy Senior Vice President, Store and Pharmacy Operations, Jared Tancrelle.

Quest Diagnostics has launched a new PCR-based diagnostic test for the Oropouche virus, enhancing U.S. preparedness for this emerging tropical disease spreading in parts of Latin America and the Caribbean.